Perceive Pharma, a pharmaceutical company pioneering novel small molecule therapeutics in ophthalmology, has announced the closing of a $15M Series A funding round including Deerfield Management, Johnson & Johnson (through its corporate venture capital organization, Johnson & Johnson Innovation - JJDC, Inc.), Braidwell LP, GV, the Retinal Degeneration Fund, and Catalio Capital Management, LP. Perceive Pharma was spun out from Perceive Biotherapeutics to accelerate development of novel neuroprotective therapeutics in glaucoma and other indications. The Company also welcomes Carol Gallagher, Pharm.D. to the Perceive Pharma Board as an independent Board Director.

Perceive Pharma is advancing novel small molecule neuroprotective therapeutics, with lead pipeline programs in glaucoma and other ophthalmic diseases. Perceive was founded on compelling research that leveraged a comprehensive screening process in retina cells to identify maximally neuroprotective biological pathways. The Company is backed by Deerfield Management, Johnson & Johnson Innovation, Braidwell LP, GV, Retinal Degeneration Fund, the venture arm of the Foundation Fighting Blindness, and Catalio Capital Management, LP.